摘要
目的观察罗沙司他在维持性腹膜透析患者肾性贫血治疗中的应用效果。方法选取进行维持性腹膜透析合并肾性贫血的70例患者作为研究对象,以随机数字表将患者分为对照组(35例)和观察组(35例)。两组患者均接受常规血液透析。对照组采用促红细胞生成素(erythropoietin,EPO)进行治疗,观察组患者采用罗沙司他进行治疗。对两组患者的治疗效果进行评估,对比治疗前后两组患者血细胞比容(HCT)、血清铁蛋白(SF)、转铁蛋白饱和度(TSAT)、C反应蛋白(CRP)、白细胞介素-6(IL-6)和肿瘤坏死因子-α(TNF-α)表达含量,并对比两组不良反应发生情况。结果观察组治疗总有效率显著优于对照组,差异有统计学意义(P<0.05);两组患者治疗前HCT、SF、TSAT表达含量差异无统计学意义(P>0.05),观察组治疗后HCT、SF、TSAT表达含量均高于对照组,差异有统计学意义(P<0.05);两组患者治疗前CRP、IL-6、TNF-α水平差异无统计学意义(P>0.05),观察组治疗后CRP、IL-6、TNF-α水平均低于对照组,差异有统计学意义(P<0.05);观察组患者不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论将罗沙司他用于维持性腹膜透析患者肾性贫血的治疗中,可提高疗效,改善贫血,抑制炎症且安全性高,值得临床推广应用。
Objective To observe the effect of roxadustat on the treatment of renal anemia in patients with maintenance peritoneal dialysis.Methods Seventy patients with maintenance peritoneal dialysis complicated with renal anemia from December 2018 to December 2019 were selected.The patients were randomly divided into control group(35 cases)and observation group(35 cases).Both groups received routine hemodialysis.The control group was treated with erythropoietin(EPO)and the observation group was treated with roxadustat.The therapeutic effects of the two groups were evaluated.The expression levels of hematocrit(HCT),serum ferritin(SF),transferrin saturation(TSAT),C-reactive protein(CRP),interleukin-6(IL-6)and tumor necrosis factor-α(TNF-α)were compared between the two groups before and after treatment.Results The total effective rate of the observation group was significantly better than that of the control group(P<0.05).There was no significant difference in the expression of HCT,SF and TSAT between the two groups before treatment(P>0.05),but the expression levels of HCT,SF and TSAT in the observation group were significantly higher than those in the control group after treatment(P<0.05).There was no significant difference in CRP,IL-6 and TNF-αlevels between the two groups before treatment(P>0.05),but the levels of CRP,IL-6 and TNF-αin the observation group were significantly lower than those in the control group after treatment(P<0.05).The incidence of adverse reactions in the observation group was significantly lower than that in the control group(P<0.05).Conclusion Roxadustat is used in the treatment of renal anemia in patients with maintenance peritoneal dialysis,which can improve curative effect,improve anemia,inhibit inflammation and had high safety,and worth clinical application.
作者
陈豫闽
刘俊英
贾国强
郭志玲
CHEN Yu-min;LIU Jun-ying;JIA Guo-qiang;GUO Zhi-ling(Department of Nephrology,First Affiliated Hospital ofHenan Unisersity of Science and Technology,Luoyang 471000,Heran,China)
出处
《广东医学》
CAS
2021年第2期216-220,共5页
Guangdong Medical Journal
关键词
罗沙司他
维持性腹膜透析
肾性贫血
roxadustat
maintenance peritoneal dialysis
renal anemia
